ACADIA PHARMACEUTICALS INCACADEarnings & Financial Report
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Revenue
$264.6M
Gross Profit
$243.8M
Operating Profit
$32.4M
Net Profit
$26.7M
Gross Margin
92.2%
Operating Margin
12.2%
Net Margin
10.1%
YoY Growth
9.3%
EPS
$0.16
ACADIA PHARMACEUTICALS INC Q2 FY2025 Financial Summary
ACADIA PHARMACEUTICALS INC reported revenue of $264.6M (up 9.3% YoY) for Q2 FY2025, with a net profit of $26.7M (down 20.1% YoY) (10.1% margin). Cost of goods sold was $20.7M, operating expenses totaled $211.5M.
Key Financial Metrics
| Total Revenue | $264.6M |
|---|---|
| Net Profit | $26.7M |
| Gross Margin | 92.2% |
| Operating Margin | 12.2% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
ACADIA PHARMACEUTICALS INC Q2 FY2025 revenue of $264.6M breaks down across 2 segments, led by Nuplazid at $168.5M (63.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Nuplazid | $168.5M | 63.7% |
| Daybue | $96.1M | 36.3% |
ACADIA PHARMACEUTICALS INC Revenue by Segment — Quarterly Trend
ACADIA PHARMACEUTICALS INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Nuplazid and Daybue) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Nuplazid | — | $174.4M | $177.5M | $168.5M |
| Daybue | — | $109.6M | $101.1M | $96.1M |
ACADIA PHARMACEUTICALS INC Annual Revenue by Year
ACADIA PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.1B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.1B |
| 2024 | $957.8M |
| 2023 | $726.4M |
| 2022 | $517.2M |
ACADIA PHARMACEUTICALS INC Quarterly Revenue & Net Profit History
ACADIA PHARMACEUTICALS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $268.1M | +9.7% | $3.6M | 1.4% |
| Q4 FY2025 | $284.0M | +9.4% | $273.6M | 96.3% |
| Q3 FY2025 | $278.6M | +11.3% | $71.8M | 25.8% |
| Q2 FY2025 | $264.6M | +9.3% | $26.7M | 10.1% |
| Q1 FY2025 | $244.3M | +18.7% | $19.0M | 7.8% |
| Q4 FY2024 | $259.6M | +12.4% | $143.7M | 55.4% |
| Q3 FY2024 | $250.4M | +18.3% | $32.8M | 13.1% |
| Q2 FY2024 | $242.0M | +46.4% | $33.4M | 13.8% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $242.0M | $250.4M | $259.6M | $244.3M | $264.6M | $278.6M | $284.0M | $268.1M |
| YoY Growth | 46.4% | 18.3% | 12.4% | 18.7% | 9.3% | 11.3% | 9.4% | 9.7% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $914.1M | $976.9M | $1.19B | $1.13B | $1.23B | $1.33B | $1.56B | $1.61B |
| Liabilities | $397.4M | $399.7M | $455.0M | $367.1M | $403.2M | $413.5M | $336.8M | $357.2M |
| Equity | $516.7M | $577.2M | $732.8M | $765.2M | $822.4M | $917.3M | $1.23B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $25.0M | $63.2M | $40.4M | $20.3M | $64.0M | $74.3M | $-48.7M |